Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valbenazine - Neurocrine Biosciences

Drug Profile

Valbenazine - Neurocrine Biosciences

Alternative Names: DYSVAL; DYSVAL capsules 40mg; INGREZZA; INGREZZA SPRINKLE; MT 5199; NBI-98854; REMLEAS; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-Biosciences

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Antipsychotics; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chorea; Drug-induced dyskinesia
  • Phase III Cerebral palsy; Schizophrenia
  • Phase II Gilles de la Tourette's syndrome

Most Recent Events

  • 21 May 2024 The US FDA label for valbenazine has boxed warning for depression and suicidal ideation and behavior in patients with huntington’s disease
  • 30 Apr 2024 Registered for Chorea in USA (PO)
  • 30 Apr 2024 Registered for Drug-induced dyskinesia in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top